Gilead Sciences, Inc. GILD entered into an exclusive option and license agreement with Tubulis, a Germany-based biotech ...

Six years after first allying with Aelix Therapeutics to test the Spanish biotech’s HTI vaccine for HIV, Gilead Sciences has ...

Justin Sullivan/Getty Images News Gilead Sciences (NASDAQ:GILD) shares logged in eight straight sessions of gains, as the ...

Gilead and Aelix first teamed up in 2018 for a clinical research collaboration agreement to investigate the vaccine.

“Gilead’s restrictions on access to lenacapavir could allow the HIV epidemic to spread. This is the closest we have ever been ...

While antiviral drugs to treat HIV had been approved a decade earlier, only five out of 33 million people who carried the ...

South Africa is a good example of a country that would benefit from the discovery of a cure. South Africa’s been providing ...

Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 ...

The Phase III Purpose 2 trial compared the safety and efficacy of twice-yearly subcutaneous lenacapavir for pre-exposure ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $75 ...

Biotech giant Gilead Sciences, Inc.’s GILD shares have risen 44.2% in the past six months compared with the industry’s growth of 1.1%. The stock has also outperformed the sector and the S&P 500. It ...

The Tampa Bay Times e-Newspaper is a digital replica of the printed paper seven days a week that is available to read on ...